Last updated 2026-09-06
- Went public on TASE (EPIT), Dec 2021
- Raised $43.7M Follow-on PO led by Barak Capital, Dec 2021
- Raised $8M Undisclosed Round led by GCB, Apr 2019
Total raised
$51.7M
Last: Public Offering 2021-12
Stage
Public
Founded
2005
Headcount
44
HQ
Caesarea, Israel
Sector
Health Tech & Life Sciences
About
Epitomee Medical is a public company developing and commercializing ingestible therapeutic devices. Their groundbreaking platform technology is based on self-expanding hydro-gel scaffolds folded into a standard pharmaceutical capsule, produced from biocompatible excipients, food additives, and food contact materials. These hydro-gel scaffolds can be engineered to be triggered by different zone-specific pH levels, allowing for optimal therapeutic effect. The company is advancing two major fields: weight management and biologic drug delivery. Their flagship product is an FDA-cleared and CE-marked ingestible capsule for weight management that expands in the stomach to create a feeling of fullness.
Funding history · 2 rounds · $51.7M total
3 events/rounds · $51.7M Total Funding: $8.0M in Private Equity, $94.7M in Public Equity
Dec 2021
★ Barak Capital★ Leumi Partners★ Nestlé Health ScienceXT Hi-techLeumi Partners Underwritingcompanies related to Udi Angelcompanies related to Idan Ofer
Apr 2019
Headcount over time
44 employees (2026-09) · 1 point
Offices
Caesarea, Israel · HQ / main office
Q&A
- What is Epitomee Medical's primary focus?
- Epitomee Medical develops and commercializes ingestible therapeutic devices, specifically drug-free capsules for diabetes prevention and weight loss.
- When did Epitomee Medical go public and on what exchange?
- Epitomee Medical went public on the TASE in December 2021, raising $51,000,000 with a valuation of $200,000,000.
- What was a significant recent regulatory achievement for Epitomee Medical?
- In September 2024, Epitomee Medical announced that the United States Food and Drug Administration (FDA) officially cleared its Epitomee® capsule weight management device.
- What was the outcome of Epitomee Medical's partnership with Nestlé Health Science?
- Epitomee Medical and Nestlé Health Science announced a partnership for the development and commercialization of the Epitomee weight loss capsule in August 2020. However, in November 2023, Nestlé canceled the agreement, causing Epitomee's stock to decline.
- What is the current employee count for Epitomee Medical?
- Epitomee Medical has 44 employees, falling within the 11-50 employee bucket.
- What is Epitomee Medical's current market capitalization?
- Epitomee Medical's market capitalization is $56,997,985.
- What is the status of Epitomee Medical's weight loss capsule in Europe?
- In March 2026, Epitomee Medical's slimming pill was approved in Europe, and the company has a distribution agreement with a German company, with sales already initiated in Israel.
Team · 17
Shimon Eckhouse
Founder · Co-Founder and Chairman of the Board
Dolev Rafaeli
Chief Executive Officer
Maya Gabrieli
CFO
Gil Cohen
VP Research & Development
Gal Aharonowitz
COO
Hadas Ashkenazi-Stapler
VP Quality Assurance and Regulatory Affairs
Alon Heth
VP Sales and Marketing
Michael (Miki) Eden
Member of the Board
Yoav Sebba
Member of the Board
Michel Habib
Member of the Board
Romina Meyer
Member of the Board
Anya Eldan
Member of the Board
Avivit Mannet Kalil
Member of the Board
Safi Landskroner
VP Business Development
Yael Kenen
VP Clinical Affairs
Ronit Koren
Board Member
Esther Baraklandes
Board Member
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2CB2B2C
Highlights
1 PatentsVerified
Tags
medical-devicesoral-drugsmedical-productsgastroenterologynon-surgicalobesitydiabetesconsumerswellness
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | Epitomee Medical Ltd. |
|---|---|
| Former names | Tulip Medical |
| Founded | 2005-8 |
| Employees (exact) | 44 |
| Market cap | $57.0M |
| Status reason | Public on TASE on Dec, 2021; |
| Wikidata QID | Q110088556 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2021-12 | TASE | EPIT | $51.0M |
Radar intelligence
Patents
| EPO | 7 |
|---|
Web history (Wayback)
| Domain | epitomeemedical.com |
|---|
Wikidata
| QID | Q110088556 |
|---|
Certificate / subdomain footprint
| Subdomains | 17 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513721803 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2005-08-15 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2017 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | הטוחן 17 קיסריה |
Recent registry events
| Date | Event |
|---|---|
| 2025-12-14 | רישום שעבוד |